THE SCIENCE

A FAMILIAR TARGET.

A DIFFERENT MOLECULE.

PDE4 sits at the intersection of inflammatory signaling and neuronal function. 11h was designed to reach the brain, engage this biology, and preserve room between activity and intolerance.


Scroll to understand the target, the discovery, the safety package, and the proof of concept.

WHY PDE4 MATTERS, AND WHY CNS DEVELOPMENT STALLED.

1970s–80s

PDE4 emerges

Researchers connect PDE4 inhibition with increased intracellular cAMP and broad anti-inflammatory effects.

1990s

Rolipram teaches the limit

CNS activity appears promising, but nausea and vomiting constrain dosing and development.

2000s–10s

The class validates

Roflumilast, apremilast, and crisaborole establish PDE4 as a druggable target in peripheral inflammatory disease.

Today

The CNS opportunity remains

A brain-optimized molecule with a usable therapeutic window could revisit the class across neurological disease.

VISUAL DIRECTION

PDE4 ACTS LIKE A BRAKE ON CAMP SIGNALING.

PDE4 breaks down cAMP inside cells.

Blocking PDE4 can amplify anti-inflammatory and neuronal signaling.

The practical question is how much inhibition the patient can tolerate.

FROM ACADEMIC DISCOVERY TO 11H.

Tell the origin story through the molecule and the scientific problem it was designed to solve.

1970s–80s

PDE4 emerges

Researchers connect PDE4 inhibition with increased intracellular cAMP and broad anti-inflammatory effects.

1990s

Rolipram teaches the limit

CNS activity appears promising, but nausea and vomiting constrain dosing and development.

2000s–10s

The class validates

Roflumilast, apremilast, and crisaborole establish PDE4 as a druggable target in peripheral inflammatory disease.

Today

The CNS opportunity remains

A brain-optimized molecule with a usable therapeutic window could revisit the class across neurological disease.

VISUAL DIRECTION

PDE4 ACTS LIKE A BRAKE ON CAMP SIGNALING.

PDE4 breaks down cAMP inside cells.

Blocking PDE4 can amplify anti-inflammatory and neuronal signaling.

The practical question is how much inhibition the patient can tolerate.